Medical Patent News

RSS

Alte Biosciences files patent for novel inflammatory bowel disease drugs

Alte Bioscience, Inc., a development stage pharmaceutical company, is pleased to announce the filing of a provisional patent for a new class of drugs that may benefit patients with inflammatory bowel disease.

3 Sep 2008

Mylan's Alphapharm victorious in Razadyne patent challenge

Mylan Inc. has announced that its subsidiary Alphapharm Pty Limited won a favorable decision in patent litigation against it and Barr Laboratories Inc. relating to Galantamine Tablets, USP, the generic version of Ortho-McNeil's Razadyne Tablets, 4 mg, 8 mg and 12 mg.

31 Aug 2008

Ortho-McNeil to appeal patent ruling on Razadyne

Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for Razadyne (galantamine hydrobromide) is invalid.

28 Aug 2008

VioQuest Pharmaceuticals issued new U.S. patent for Lenocta

VioQuest Pharmaceuticals today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta (sodium stibogluconate). U.S. Patent No. 7,416,723 entitled "Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases," encompasses novel compositions including Lenocta for the treatment of cancer and a broad range of other diseases.

26 Aug 2008

Meda settles U.S. Astelin patent litigation with Cobalt

Meda, through its wholly owned U.S. subsidiary, Meda Pharmaceuticals Inc., has entered into a settlement agreement with Cobalt Pharmaceuticals Inc. (hereafter Cobalt) that resolves the U.S. patent litigation between the companies regarding Cobalt's proposed generic version of Astelin.

25 Aug 2008

BioAlliance Pharma granted patent on Lauriad technology in Europe

The patent describes and protects a muco-adhesive tablet for various applications in the field of opportunistic infections associated with AIDS and cancer. It has been validated in the main European countries and the opposition period has now expired.

24 Aug 2008

Watson announces ruling in Naproxen sodium patent case

Watson Pharmaceuticals, Inc. announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan, infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent").

13 Aug 2008

SpectraScience awarded U.S. patent for correcting image misalignment

SpectraScience, Inc. has announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."

13 Aug 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

IMPAX sued for patent infringement on generic Ultram ER

IMPAX Laboratories, Inc. today announced Purdue Pharma Products L.P. ("Purdue"), Napp Pharmaceutical Group Ltd. ("Napp"), Biovail Laboratories International, SRL ("Biovail") and Ortho-McNeil, Inc. ("Ortho-McNeil") have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company's submission of its Abbreviated New Drug Application ("ANDA") for tramadol hydrochloride extended-release tablets (100 mg), generic of Ultram ER, to the Food and Drug Administration.

12 Aug 2008

Ulysses Pharma issued U.S. patent for novel class of antibiotics

Ulysses Pharma has announced the issuance of US Patent 7,410,974, covering its novel class of antibiotics which target drug resistant bacteria.

12 Aug 2008

USPTO issues patent for methodologies for abating a broad range of allergens, pathogens, viruses, bacteria

The United States Patent & Trademark Office issued a patent for an environmentally "Green" low cost process that eliminates the effects of a broad range of pollutants using oxidants.

5 Aug 2008

Barr confirms Xyzal tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiaries, Barr Laboratories, Inc. and PLIVA-Hrvatska D.O.O., have initiated a challenge of the patent listed by UCB Inc. in connection with its Xyzal(R) Tablets (levocetirizine dihydrochloride), 5mg.

31 Jul 2008

DNA Heritage overcomes patent claims

DNA Heritage has recently overcome patent claims held by a competitor which would have severely restricted the use of DNA testing and databases that allow families around the world to match and connect up through their DNA.

30 Jul 2008

Barr confirms patent challenge of Sensipar tablets

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.

29 Jul 2008

Barr confirms Fentora tablet patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Cephalon, Inc. in connection with its Fentora(R) Tablets (fentanyl citrate buccal tablets), equivalent to fentanyl base 100 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jul 2008

Cargill awarded patent for technology in taste tissue imaging

Cargill has received a patent for a breakthrough technology in taste tissue imaging and taste modification that is superior to the cell screening technology currently available in the flavor, food and beverage industries.

23 Jul 2008

Patent for Aciphex ruled valid and enforceable

PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for Aciphex (rabeprazole sodium 20 mg tablets) is valid and enforceable.

21 Jul 2008

China Medicine Corporation grated Australian patent for recombinant Aflatoxin Detoxifizyme

China Medicine Corporation announced today that it obtained a patent from Australia Patent Office for recombinant Aflatoxin Detoxifizyme (rADTZ). The patent is valid through January 13, 2025.

17 Jul 2008

Sale of liver disease therapeutic patents

IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.

17 Jul 2008